Business Corpus: Bausch Health Tops Expectations, Maintains 2018 Sales GuidanceBausch Health, formerly Valeant Pharmaceuticals, on Tuesday reported losses of $2.49 per share on $2.13 billion in sales for its second quarter. The post Bausch Health Tops Expectations, Maintains 2018 Sales Guidance appeared first on Investor's Business Daily.

[Collection]

Bausch Health (BHC) on Tuesday reported earnings that appeared to come in well ahead of analyst views, lifting the company's shares in premarket trades.

Formerly known as Valeant Pharmaceuticals, Bausch Health reported a net loss of $2.49 per share on $2.13 billion in sales for its second quarter. While the company didn't report adjusted income, calculations show it was 93 cents per share. Analysts polled by Zacks Investment Research had called for adjusted income of 81 cents a share and $2.05 billion in sales.

In the year-earlier period, the firm reported a net loss of 11 cents per share on $2.23 billion in sales. Adjusted income was $1.03 in the year-ago period.

For the year, Bausch Health predicted $8.15 billion to $8.35 billion in sales. Analysts predict adjusted profit of $3.41 per share and $8.3 billion in sales.